ABSL Pharma and Healthcare Direct Growth: NAV Today, Performance Review and Should You Invest?

ABSL Pharma and Healthcare Direct Growth is an open ended equity scheme with concentrated exposure to a specific sector or investment theme, offered by Aditya Birla Sun Life Mutual Fund. This review covers the latest NAV, historical returns, plan details and whether it fits your investment goals as an open ended equity scheme.

The scheme carries ISIN INF209KB1O25 and is classified under Equity Scheme – Sectoral/ Thematic. Read on for a full breakdown of ABSL Pharma and Healthcare Direct Growth NAV history and returns before you decide how it fits your portfolio.

Click Here – Get Free Investment Predictions

About ABSL Pharma and Healthcare Direct Growth

ABSL Pharma and Healthcare Direct Growth is offered by Aditya Birla Sun Life Mutual Fund and was first launched on 11-07-2019, giving it a track record of about 7.0 years. The scheme falls under the Equity Scheme – Sectoral/ Thematic category as classified by AMFI.

This particular scheme code represents a Direct Plan, which is bought straight from the fund house without a distributor, so it usually carries a lower expense ratio than the Regular Plan of the same scheme, structured under the Growth option, where profits are reinvested in the scheme and reflected in a rising NAV instead of being paid out. Investors evaluating ABSL Pharma and Healthcare Direct Growth should confirm they are selecting the correct plan and option combination that matches their needs before investing.

Aditya Birla Sun Life Mutual Fund is registered with SEBI and, like every other fund house, reports scheme performance and portfolio holdings to AMFI on a regular basis. Every mutual fund scheme in India, regardless of the AMC that manages it, is governed by SEBI Mutual Fund Regulations, which set rules around disclosure, expense ratios and investor protection that fund houses must follow.

ABSL Pharma and Healthcare Direct Growth NAV and Performance

As on 21-07-2026, ABSL Pharma and Healthcare Direct Growth NAV stands at Rs 40.3600. The table below summarises its performance across available time periods, calculated using official historical NAV data.

Metric	Value
Current NAV	Rs 40.3600 (as on 21-07-2026)
1 Year Return	+17.51%
3 Year CAGR	+23.95%
5 Year CAGR	+15.00%
Since Inception Cagr	+21.87%
Inception Date	11-07-2019
Category	Equity (Very High Risk)

ABSL Pharma and Healthcare Direct Growth returns shown above are point to point and computed from official historical NAV data. Returns for periods below 1 year are absolute, while 1 year and above are shown as CAGR (compounded annual growth rate).

ABSL Pharma and Healthcare Direct Growth: Plan and Option Explained

ABSL Pharma and Healthcare Direct Growth is structured as a Direct Plan. In India, every open ended mutual fund scheme typically offers both a Direct Plan and a Regular Plan. The Direct Plan is bought straight from the AMC without a distributor and carries a lower expense ratio, while the Regular Plan of the same underlying portfolio is bought through a distributor and carries a marginally higher expense ratio that compensates the distributor.

On the option side, ABSL Pharma and Healthcare Direct Growth uses the Growth option, where profits are reinvested in the scheme and reflected in a rising NAV instead of being paid out. Investors who want compounding without receiving cash payouts typically prefer Growth, while those who want periodic cash flow may prefer an IDCW or Dividend option, keeping in mind that payouts reduce the NAV to that extent.

Should You Invest in ABSL Pharma and Healthcare Direct Growth?

Whether ABSL Pharma and Healthcare Direct Growth suits you depends on your risk appetite, time horizon and financial goal. Suited only to investors who understand the underlying sector or theme and can tolerate sharp cyclical swings. It sits in the Equity category, which is classified as Very High Risk, so investors should size their allocation to this scheme according to how much volatility they can tolerate.

Investors considering ABSL Pharma and Healthcare Direct Growth should also compare it against other schemes in the same equity category using a screener, check the expense ratio and exit load in the latest factsheet, and align the investment horizon with the recommended holding period for this category before committing fresh money.

Compare ABSL Pharma and Healthcare Direct Growth Against Other Equity Funds on the Univest Screener

How to Invest in ABSL Pharma and Healthcare Direct Growth via Univest

To invest in ABSL Pharma and Healthcare Direct Growth, log in to your Univest account and complete your KYC if you have not already done so. Search for it by scheme name or AMC within the mutual fund section.

Decide between a lumpsum investment or a monthly SIP based on your cash flow, enter the amount, and confirm the order. You can track ABSL Pharma and Healthcare Direct Growth NAV and returns anytime from your Univest portfolio dashboard.

Download the Univest iOS App or Univest Android App to track ABSL Pharma and Healthcare Direct Growth NAV live and manage your mutual fund portfolio.

Risks of Investing in ABSL Pharma and Healthcare Direct Growth

• Returns depend heavily on how one sector or theme performs, unlike a diversified fund.
• Sector cycles can be sharp, leading to periods of underperformance.
• Not recommended as a core, standalone holding.

These risks apply broadly to the Equity category that ABSL Pharma and Healthcare Direct Growth belongs to. Always read the Scheme Information Document (SID) of this scheme for the complete, fund specific risk factors before investing.

Conclusion

ABSL Pharma and Healthcare Direct Growth is an open ended equity scheme with concentrated exposure to a specific sector or investment theme. With a current NAV of Rs 40.3600 and a since inception CAGR of +21.87%, it has a track record investors can evaluate against their own goals. As with any equity investment, review the latest factsheet, expense ratio and exit load and consult your financial advisor to check suitability before investing. This article is for informational purposes as per SEBI RA INH000013776.

FAQs on ABSL Pharma and Healthcare Direct Growth

What is the current NAV of ABSL Pharma and Healthcare Direct Growth?

Ans. Its latest available NAV is Rs 40.3600 as on 21-07-2026. NAV changes every business day based on the value of the securities the scheme holds.

What are the returns of ABSL Pharma and Healthcare Direct Growth?

Ans. It has delivered a 1 year return of +17.51%, a 3 year CAGR of +23.95% and a 5 year CAGR of +15.00%. Past returns do not guarantee future performance.

Can I invest in ABSL Pharma and Healthcare Direct Growth right now?

Ans. Yes, it is an open ended scheme, which means investors can generally invest or redeem units on any business day at the applicable NAV, subject to any exit load mentioned in the scheme documents.

Is ABSL Pharma and Healthcare Direct Growth a Direct Plan or a Regular Plan?

Ans. This specific scheme is the Direct Plan. a Direct Plan, which is bought straight from the fund house without a distributor, so it usually carries a lower expense ratio than the Regular Plan of the same scheme.

What is the Growth option in ABSL Pharma and Healthcare Direct Growth?

Ans. It is structured under the Growth option, where profits are reinvested in the scheme and reflected in a rising NAV instead of being paid out.

What category does ABSL Pharma and Healthcare Direct Growth belong to and how risky is it?

Ans. It falls under the Equity category and is classified as Very High Risk. Suited only to investors who understand the underlying sector or theme and can tolerate sharp cyclical swings.

How can I check ABSL Pharma and Healthcare Direct Growth live on Univest?

Ans. You can track its NAV, category peers and other mutual fund and stock data through the Univest Screener and app after logging in to your Univest account.

Who manages ABSL Pharma and Healthcare Direct Growth?

Ans. It is managed by Aditya Birla Sun Life Mutual Fund as per the fund house’s official scheme disclosures. Fund manager names can change over time, so investors should check the latest factsheet on the AMC website for the current manager.